At the conference, SciBase presented its product Nevisense – an AI-powered detection enhancement technology that improves the ability for early detection of melanoma at point of care. Melanomas have a fast growth rate and a delay in treatment may mean the difference between life and death. Early detection is the key to survival as melanoma… Keynote speakers presented Nevisense at the 2024 Winter Clinical Dermatology Conference in Miami weiterlesen
Skin barrier function has been implicated as a driving factor in many dermatological disorders, including Atopic Dermatitis (AD). AD is one of the most prevalent disorders in the world, affecting up to 20% of children globally. Additionally, skin barrier function is commonly assessed in the research and development of pharmaceutics and cosmetic products. The study… New study shows Nevisense evaluates skin barrier function with less sensitivity to lifestyle factors than TEWL weiterlesen
The research reports, analyst comments and interview videos will be published and made available on inderes.se, inderes.dk and inderes.fi with over 70,000 active members, as well as through Inderes‘ channels on social media and other investor platforms. The first analysis is planned to be carried out in the first quarter of 2024. Inderes welcomes all… SciBase initiates collaboration with Inderes for commissioned research weiterlesen
SciBase has evolved from being an innovation company originating from the Karolinska Institute to a global company dedicated to supporting healthcare professionals in their work by facilitating early detection and prevention of skin cancer and other dermatological conditions. During SciBase’s Capital Markets Day, Pia Renaudin, who assumed the role of CEO in October 2023, will… Reminder: Welcome to SciBase Capital Markets Day 2024 weiterlesen
SciBase has evolved from being an innovation company originating from the Karolinska Institute to a global company dedicated to supporting healthcare professionals in their work by facilitating early detection and prevention of skin cancer and other dermatological conditions. During SciBase’s Capital Markets Day, Pia Renaudin, who assumed the role of CEO in October 2023, will… Welcome to SciBase Capital Markets Day 2024 weiterlesen
SciBase has gone from being an innovation Company originating from the Karolinska Institute to a global company that supports physicians in their work by enabling early detection and prevention in skin cancer and other skin diseases. During SciBase’s capital markets day, Pia Renaudin, CEO since October 2023, will discuss SciBase’s way forward, updated strategy and… SciBase capital markets day 2024 – save the date weiterlesen
„Through our new partnership with Nevisense, we are now one of the first groups in the country to adopt AI technology that will help our clinicians improve patient outcomes,“ said Dr. Simon Madorsky, medical director and founder of the Skin Cancer and Reconstructive Surgery Center. Dr. Madorsky is also the CME Chair of the SCARS… Skin Cancer and Reconstructive Surgery Center of California Adopts AI-driven Nevisense for early skin cancer detection weiterlesen
„We are excited to integrate the Nevisense test during routine skin exams in several of our California offices and offer our patients the latest AI-driven technology for the earliest possible detection of melanoma. Melanoma is the deadliest form of skin cancer, but when detected early, treatment has a nearly 100% cure rate. Early testing and… SciBase and Skin and Cancer Institute partner to advance AI-driven skin cancer detection in California weiterlesen
Thomas Axelsson (Gell Group), Dharminder Chahal (VanHerk Group), Peter Elmvik (Stockholms Elbolag), Tord Lendau (Chairman of the Board). The appointments have been made in accordance with the instructions regarding principles for the appointment of the company nominating committee which were determined at the Annual General Meeting of SciBase Holding on May 17, 2023. The Annual… Nomination Committee appointed for SciBase Holding’s Annual General Meeting in 2024 weiterlesen
Skin barrier research comprises one of the fastest-growing fields within the dermatology community, including the development of new therapeutics, testing cosmetics, and beauty products, testing other consumer goods, and the scientific investigation of diseases related to the skin barrier. Nevisense and its underlying Electrical Impedance Spectroscopy (EIS) technology were used to assess the effect of… Nevisense detects skin barrier damage from skin models in research weiterlesen
